ABSTRACT
INTRODUCTION
Neonatal sepsis is a clinical syndrome characterized by systemic signs of infection and accompanied by bacteremia in the first month of life (1) . Sepsis occurring in the first 72 hours of life is defined as early-onset sepsis (EOS) (2) (3) (4) and that occurring beyond 72 hours as late-onset sepsis (LOS) (5, 6) . Newborns are relatively immunocompromised to deal with an infection due to the deficiencies in their humoral immunity. In addition, preterm neonates have decreased complement factors, opsonic activity, and polymorphonuclear chemotaxis and are more prone to such infections and further complications (7, 8) . Therefore, the incidence of severe sepsis and septic shock is higher among preterm infants. Incidence of newborn infection accounts for high neonatal morbidity and mortality in most societies in spite of recent advances in intensive care. Thus, prevention of neonatal sepsis has remained a global challenge in the recent decades (9) (10) (11) (12) (13) . In this regard, adjunctive sepsis treatment regimens to neutralize or antagonize endotoxin, presumptive antibiotic coverage, and sepsis mediators are the treatment of choice for infants with symptoms, signs, or risk factors of sepsis. However, their efficacy is still variable and limited.
On the other hand, the role of intravenous immunoglobulin (IVIG) as an adjunctive treatment in sepsis has been shown in experimental and clinical trials due to its positive effects on the infant's immune system (13) (14) (15) . The pathophysiological causes for administration of IVIG composed of complement activation, neutralization of endotoxin and a wide variety of super-antigens, enhancement of opsonization and phagocytosis, and modification of endotoxin-released cytokines or mononuclear blood cells. However, the majority of healthcare authorities believe that, due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidence remains insufficient to support the efficacy of intravenous immunoglobulin G (IVIG) in prevention of preterm neonatal sepsis (15) (16) (17) (18) (19) . The present controlled clinical trial was carried out with the objective of determining the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.
MATERIALS AND METHODS

Study Design and setting
This single blind randomized controlled trial was performed in pediatric hospital of Hormozgan Province in Iran in 2015. The hospital is the largest tertiary care pediatric center in the south of Iran. Parents of infants were informed about the aim of this intervention and probable side effects; after obtaining informed consent and institutional review board approval of Hormozgan University of Medical Sciences, they were randomly assigned to the control group and the intervention group.
Participants
Infants who were born alive before 37 weeks of pregnancy (preterm neonates) and infants under 2500 g at birth, low birth weight (LBW) infants, were recruited in the study. Patients underwent physical examinations at the screening visit by the neonatologist. Thereafter, demographic characteristics, history of related risk factors, and results of physical examinations were recorded for each participant in a pre-designed data collection sheet. Infants with lethal anomaly, congenital heart disease, TORCH infection, and severe asphyxia were excluded from the investigation.
Diagnosis
All of the infants underwent the diagnostic tests, including blood culture, complete blood count (CBC), and Creactive protein (CRP) estimation. The diagnosis of septicemia was confirmed by a positive blood culture or by clinical examinations with positive results of CBC and CRP tests.
Interventions
All of the infants underwent sepsis workup while admitted to the neonatal unit. The intervention group received IVIG in addition to routine and general care, including antibiotic treatment, while the control group was given routine and general care without IVIG. IVIG was given to members of the intervention group as slow intravenous infusion at a dose of 500mg/kg within 12 h and 3 days of birth, respectively.
Outcome
At the end of first week, the reassessment of sepsis was carried out, and the findings were recorded. Comparison of mortality rate (due to sepsis or its associated complications), total number of days of hospitalization, incidence of intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and bronchopulmonary dysplasia (BPD) between two groups were considered as the outcome of treatment.
Research Ethics
A written informed consent was obtained from the parents of all study participants. The patients' information was kept confidential. The study is confirmed by the ethics committee of Hormozgan University of Medical Sciences (HUMS). ClinicalTrials.gov Identifier: NCT02954926. Ethical approval code was HUMS.REC.1394.162.
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Statistical analyses
Statistical analysis was conducted by SPSS version 19 (SPSS Inc, Chicago, IL, USA). The data are expressed as means ± standard deviation and number (%). Chi-square test was used to compare the categorical variables, and Independent-samples-t-test was used to compare continuous variables between the two groups. A two-sided α = 0.05 was considered statistically significant.
RESULTS
Baseline characteristics
Total 92 infants were enrolled, 46 in intervention and 46 in the control group, and no participants were excluded from the study during the research period (Figure 1) . No statistically significant difference was reported based on age, gestational age, birth weight, and gender between the groups (Table 1 ). 
DISCUSSION
In the present investigation, both groups were comparable for mean age, birth weight, gender, and mean gestational age. Findings of present trial revealed that administration of IVIG as an adjunctive treatment (in addition to standard therapy) reduced the prevalence of sepsis and its subsequent complications including C-reactive protein and positive blood culture. Also, based on our findings IVIG significantly reduced the duration of hospitalization. In accordance with our results, several authors indicated a significant improvement in the condition of septic infants given antibiotics plus IVIG in comparison with neonates given antibiotics but not treated with IVIG, identifying the beneficial role of IVIG as useful adjunctive therapy (20, 21) . On the contrary, several trials have illustrated no impact of IVIG in treatment and prevention of neonatal sepsis in premature newborns. Therefore, a systematic review by Cochrane collaboration (2004) examined the association between IVIG therapy and treatment in premature and term infants. Although the evaluated studies were different in the dosing regimens, variety of IVIG products, and study populations, a significant reduction was observed in sepsis and its related complications (22) . Recently, Cochrane updated its previous systematic review of IVIG for infection in infants with suspected or proven infection. Combining the findings of 10 documents carried out in eight countries revealed that sepsis and its complications reduced among neonates with clinically suspected infection and also subsequently proven infection (RR 0.58; 95% CI, 0.38 to 0.89 and RR 0.55; 95% CI, 0.31 to 0.98) (15) . However, a recent large multicenter (113 sites), randomized, double blinded, placebo controlled study (13) evaluated the safety and efficacy of IVIG therapy in newborns. In a follow-up of 2-year-old infants, there were no significant differences in the rates of major or nonmajor disability or of adverse events, including the incidence of subsequent sepsis episodes (13) . Finally, a systematic review by Ohlsson and Lacy (15) evaluated 26 studies for the role of IVIG in neonatal sepsis and its complications. The global effect of this outcome described that IVIG administration results in a significant reduction in sepsis and in one or more episodes of any serious infections (15) . Findings of the present trial should be reported with caution because this study was limited in various ways. First, design of the present work was a single-blind randomised controlled trial, which elevated the bias in comparison with double-blind studies. Second, this is a single center study with limited patients and study population. Third, there was no case with necrotizing enterocolitis, bronchopulmonary dysplasia, and death in our investigation, which made us unable to compare the study groups in those variables. Therefore, it is suggested to consider these items in further investigations.
